MedPath

Gait Analysis in MPS IVA

Completed
Conditions
MPS IVA
Morquio Syndrome
Registration Number
NCT01920828
Lead Sponsor
Oregon Health and Science University
Brief Summary

The purpose of this study is to learn about gait (walking) characteristics in MPS IVA and possible changes in gait with enzyme replacement therapy.

Detailed Description

The purpose of this 3-year study is to conduct a longitudinal investigation using motion analysis of gait to objectively and quantitatively assess gait characteristics of MPS IVA patients. Data documenting gait characteristics and abnormalities will be gathered in patients initiating enzyme replacement therapy.

Inclusion criteria Individuals with MPS IVA diagnosed by enzyme or molecular studies Exclusion Criteria Individual with MPS IVA previously enrolled in BMN-110 Individual is non-ambulatory The individual is unable to complete longitudinal study visits at least yearly

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
10
Inclusion Criteria

-Diagnosis of MPS IVA

Read More
Exclusion Criteria

Non-ambulatory

  • Previous enrolled in clinical trial BMN-110
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Measurable changes in gait36 months

Data acquired on patients will be compared with age-matched standardized norms. The normal data is available from a pre-existing Gait Repository, a collection of gait parameters in children without a specific diagnosis studied at Oregon Health and Science University. The results will be converted to centile charts with the aid of a biostatistician. Centile charts will be used to track statistical changes over time in the following gait parameters including but not exclusive to: velocity, cadence, step length, and base of support.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Oregon Health and Science University

🇺🇸

Portland, Oregon, United States

© Copyright 2025. All Rights Reserved by MedPath